Eterna Therapeutics Inc

Three biotech companies delivered distinct catalysts. NeOnc Technologies received FDA feedback on its CMC program for lead candidate NEO212, canceling a planned meeting after deeming the written responses sufficient, and expects topline Phase 2a data for NEO100 by the end of July. Ernexa Therapeutics reported independently validated preclinical results for ERNA-101, showing 67% complete tumor clearance in an ovarian cancer model when combined with anti-PD-1 therapy, ahead of a planned IND submission in the third quarter of 2026. VivoSim Labs received a $5 million milestone payment from Eli Lilly after the first patient was dosed in a Phase 2 study of a divested IBD program, and issued guidance projecting more than 500% revenue growth in Fiscal Year 2027 driven by adoption of its NAMs human tissue testing platform.

PayPal Holdings surged more than 20% in premarket trading after Reuters reported that payments giant Stripe and private equity firm Advent International submitted a joint takeover offer valuing the company at more than $53 billion. The consortium offered $60.50 per share, a roughly 28% premium to PayPal's previous close. The proposed acquisition would be one of the largest fintech deals in years. Separately, Aehr Test Systems rallied 29% after fiscal fourth-quarter adjusted earnings of $0.11 per share beat expectations for a $0.01 loss, with revenue up 33% year-on-year to $18.8 million. Ernexa Therapeutics soared 30% on preclinical data for its ovarian cancer therapy candidate, Redwire Corp. rose 4.6% on $21.5 million in follow-on orders for Stalker unmanned aerial systems, and XPeng gained 4% after the Wall Street Journal reported plans to launch a humanoid robot globally in 2027 with monthly production capacity exceeding 1,000 units by year-end. On the downside, Pentair tumbled nearly 20% after cutting its full-year outlook, announcing the CFO's departure, and disclosing preliminary second-quarter sales well below guidance due to inventory destocking in its pool products business.

Ernexa Therapeutics announced it is on track to submit an Investigational New Drug application for its lead oncology candidate ERNA-101 in the third quarter of 2026, positioning the company to become clinical-stage. Manufacturing process development is complete, GMP production is underway, and IND-enabling studies are advancing, with a first-in-human Phase 1 study planned for the fourth quarter of 2026. Preclinical data showed that ERNA-101 combined with PD-1 blockade eliminated tumors and achieved 100% long-term survival in animal models. The company also expects to hold a pre-IND meeting with the FDA for its autoimmune disease program ERNA-201 in the fourth quarter of 2026. Ernexa completed a $10.5 million financing and believes it has sufficient resources to reach key milestones over the next 12 to 18 months.